CLINICAL TRIALS PROFILE FOR PIFLUFOLASTAT F-18
✉ Email this page to a colleague
All Clinical Trials for PIFLUFOLASTAT F-18
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05394259 ↗ | A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer | Not yet recruiting | Lantheus Medical Imaging | Early Phase 1 | 2022-11-30 | To learn if piflufolastat F18 can be used in imaging scans for patients with breast cancer, HCC, or pancreatic cancer |
| NCT05394259 ↗ | A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer | Not yet recruiting | M.D. Anderson Cancer Center | Early Phase 1 | 2022-11-30 | To learn if piflufolastat F18 can be used in imaging scans for patients with breast cancer, HCC, or pancreatic cancer |
| NCT05919329 ↗ | Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy | Not yet recruiting | Oregon Health and Science University | Phase 4 | 2024-05-01 | This clinical trial investigates the change in prostate-specific membrane antigen (PSMA) expression in response to hormonal therapy in both, Castration Sensitive Prostate Cancer (CSPC) and Castration Resistant Prostate Cancer (CRPC), and whether this change in PSMA expression changes tumor staging after therapy initiation. Understanding these effects can help define the best timing to perform the PSMA positron emission tomography (PET) relative to the start of therapy. |
| NCT05919329 ↗ | Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy | Not yet recruiting | Progenics Pharmaceuticals, Inc. | Phase 4 | 2024-05-01 | This clinical trial investigates the change in prostate-specific membrane antigen (PSMA) expression in response to hormonal therapy in both, Castration Sensitive Prostate Cancer (CSPC) and Castration Resistant Prostate Cancer (CRPC), and whether this change in PSMA expression changes tumor staging after therapy initiation. Understanding these effects can help define the best timing to perform the PSMA positron emission tomography (PET) relative to the start of therapy. |
| NCT05919329 ↗ | Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy | Not yet recruiting | OHSU Knight Cancer Institute | Phase 4 | 2024-05-01 | This clinical trial investigates the change in prostate-specific membrane antigen (PSMA) expression in response to hormonal therapy in both, Castration Sensitive Prostate Cancer (CSPC) and Castration Resistant Prostate Cancer (CRPC), and whether this change in PSMA expression changes tumor staging after therapy initiation. Understanding these effects can help define the best timing to perform the PSMA positron emission tomography (PET) relative to the start of therapy. |
| NCT05939414 ↗ | An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. | Recruiting | Novartis Pharmaceuticals | Phase 3 | 2024-03-12 | The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PIFLUFOLASTAT F-18
Condition Name
Clinical Trial Locations for PIFLUFOLASTAT F-18
Trials by Country
Clinical Trial Progress for PIFLUFOLASTAT F-18
Clinical Trial Phase
Clinical Trial Sponsors for PIFLUFOLASTAT F-18
Sponsor Name
